Odyssey Therapeutics

Odyssey Therapeutics, Inc. (Nasdaq: ODTX) is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology. The company states that it targets upstream signaling nodes and mechanisms such as those in the innate immune system to prevent pathological inflammation before it occurs, an approach it says differentiates it from existing therapies targeting adaptive immune responses. It reports having built a pipeline of small molecule and protein therapeutics, and describes a replicable and scalable model for drug discovery and development. Its lead program, OD-001, is a small molecule RIPK2 scaffolding inhibitor, and it describes OD-002 as an oral SLC15A4 inhibitor designed to selectively modulate pathogenic B cell populations to treat autoimmune disease.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company that states it seeks to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology. The company says it targets upstream signaling nodes and mechanisms like those in the innate immune system to prevent pathological inflammation before it occurs, an approach it describes as differentiating it from current therapies targeting adaptive immune responses. It reports having built a pipeline of small molecule and protein therapeutics designed to precisely target disease pathology, prioritizing targets where it believes the underlying disease biology is understood and diseases with unmet need and large patient populations. The company describes a replicable and scalable model for drug discovery and development and says it brings together talent from pharma and biotech. In its second quarter 2026 update, the company reported that data from the Phase 2a monotherapy trial of OD-001 were accepted for oral presentation at United European Gastroenterology Week in October, that a Phase 2a combination trial of OD-001 with vedolizumab and a Phase 2b monotherapy trial of OD-001 were expected to initiate in the second half of 2026, and that cash on hand as of June 30, 2026 was $433.1M, expected to fund operations into the second half of 2028. It also stated plans to file a CTA for its second clinical program, OD-002, an oral SLC15A4 inhibitor designed to selectively modulate pathogenic B cell populations to treat autoimmune disease, by the end of that year.

A clinical-stage biopharmaceutical company seeking to transform the standard of care for autoimmune and inflammatory diseases by targeting upstream signaling nodes and mechanisms to prevent pathological inflammation before it occurs.

• OD-001

  Small molecule RIPK2 scaffolding inhibitor; data from its Phase 2a monotherapy trial were accepted for oral presentation at United European Gastroenterology Week in October, and a Phase 2a combination trial with vedolizumab and a Phase 2b monotherapy trial were expected to initiate in 2H 2026.

• OD-002

  An oral SLC15A4 inhibitor designed to selectively modulate pathogenic B cell populations to treat autoimmune disease; the company planned to file a CTA by the end of 2026.

1. 1Odyssey Therapeuticsodysseytx.com
2. 2About Odyssey Therapeuticsodysseytx.com
3. 3Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateinvestors.odysseytx.com
4. 4Odyssey Therapeutics (United States)wikidata.org